Citrullinemia type I is an inherited urea cycle disorder caused by pathogenic variants in the ASS1 gene. Argininosuccinate synthetase 1 deficiency prevents the proper elimination of excess nitrogen, leading to the accumulation of ammonia and citrulline in the blood, with a risk of severe neurological damage.
Citrullinemia
Citrullinemia type I (CTLN1) is an autosomal recessive metabolic disorder. To develop the condition, a person must inherit two altered copies of the ASS1 gene, one from each parent. This gene encodes the enzyme argininosuccinate synthetase 1, which catalyzes the third step of the urea cycle, in which citrulline combines with aspartate to form argininosuccinate. This process allows nitrogen from protein metabolism to be converted into urea, which can be eliminated in the urine.
Pathogenic variants in ASS1 reduce or abolish enzyme activity and disrupt the urea cycle. As a consequence, ammonia accumulates in the blood along with elevated citrulline, generating a state of hyperammonemia that is particularly toxic to the central nervous system. Citrullinemia type I is the second most common urea cycle disorder and is estimated to occur in around 1 in 220,000 births, although the frequency can vary between populations.
Symptoms
The classic form usually manifests in the first days of life, after an apparently normal initial period. Newborns may present feeding refusal, vomiting, lethargy, irritability, hypotonia, respiratory distress, and altered level of consciousness. Without urgent treatment, hyperammonemia can progress to seizures, cerebral edema, coma, and death. There are late-onset forms, from infancy to adulthood, with intermittent episodes of headache, vomiting, confusion, ataxia, behavioral changes, or psychiatric symptoms, often triggered by infections, fasting, pregnancy, postpartum, or excessive protein intake.
Disease management
Management seeks to prevent hyperammonemic crises and limit neurological damage. It includes individualized protein restriction, sufficient caloric intake to avoid catabolism, arginine supplementation, and essential amino acid formulas under metabolic supervision. Nitrogen-scavenging drugs, such as sodium benzoate, sodium phenylbutyrate, or glycerol phenylbutyrate, promote alternative nitrogen excretion pathways. Emergency protocols are required during illnesses, fasting, or surgical procedures. Liver transplantation may be considered in severe or recurrent cases, as it corrects the liver defect, although it does not reverse prior neurological damage.
Genes analyzed
Bibliography
Diez-Fernandez C, Rüfenacht V, Häberle J. Mutations in the Human Argininosuccinate Synthetase (ASS1) Gene, Impact on Patients, Common Changes, and Structural Considerations. Hum Mutat. 2017 May;38(5):471-484.
Quinonez SC, Lee KN. Citrullinemia Type I. 2004 Jul 7 [updated 2022 Aug 18]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Rüegger CM, Lindner M, Ballhausen D, et al. Cross-sectional observational study of 208 patients with non-classical urea cycle disorders. J Inherit Metab Dis. 2014 Jan;37(1):21-30.
